

UNCLASSIFIED

**TAB D TO MOD SEVENTEEN TO USCENTCOM INDIVIDUAL PROTECTION AND INDIVIDUAL-UNIT DEPLOYMENT POLICY: THEATER REQUIREMENTS FOR MEDICAL CHEMICAL BIOLOGICAL RADIOLOGICAL NUCLEAR (CBRN) DEFENSE MATERIEL (MCDM)**

UNCLASSIFIED//

REF A/ORD/CDRUSCENTCOM/1 DEC 17//  
AMPN/USCENTCOM OPORD 05-03, ANTI-TERRORISM//

REF/B/MSG/USCENTCOM/SG/031815Z MAR 19//  
AMPN/MOD FOURTEEN TO USCENTCOM INDIVIDUAL PROTECTION AND UNIT DEPLOYMENT POLICY MESSAGE//

REF/C/DOC/USCENTCOM/12 JUL 16//  
AMPN/USCENTCOM REGUALTION 40-4, MEDICAL LOGISTICS FOR HEALTHCARE OPERATIONS//

REF/D/DOC/OFFICE OF SECRETARY OF DEFENSE/19 JUN 19// AMPN/DODI 6490.03, DEPLOYMENT HEALTH//

REF/E/MSG/JOINT PROGRAM EXECUTIVE OFFICE - CHEMICAL BIOLOGICAL DEFENSE/20 JUN 19//  
AMPN/MEDICAL MATERIAL QUALITY CONTROL MESSAGE (MMQC)-19-2097 2-PAM / CANA / AUTOINJECTORS / MERIDIAN MEDICAL TECHNOLOGIES INC. (MMT) / UPDATE//

**1. (U) PURPOSE.** THIS TAB SETS MCDM REQUIREMENTS FOR THE USCENTCOM THEATER.

**2. (U) APPLICABILITY.**

**2.A. (U)** THIS GUIDANCE APPLIES TO ALL US MILITARY SERVICE MEMBERS AND DEPARTMENT OF DEFENSE (DOD) CIVILIANS IN THE USCENTCOM AOR FOR 15 DAYS OR MORE. MCDM IS NOT REQUIRED FOR PERSONNEL IN THE AOR LESS THAN 15 DAYS UNLESS SPECIFIED BY THE SUPPORTED COMMANDER.

**2.B. (U)** THIS GUIDANCE APPLIES TO SELECT DOD CONTRACTORS IN MANNER DIRECTED BY REF A (ANNEX W, PARAGRAPH 8.C.) CONSISTENT WITH THE TIME IN THEATER REQUIREMENTS DICTATED IN PARAGRAPH 2.A. OF THIS MESSAGE.//

**3. (U) GENERAL.**

**3.A. (U)** THIS POLICY IS A DEPARTURE FROM PREVIOUS VERSIONS OF MCDM GUIDANCE IN THE USCENTOM INDIVIDUAL PROTECTION AND INDIVIDUAL-UNIT DEPLOYMENT POLICY AS IT MOVES SELECT ITEMS LISTED IN PARAGRAPH 4 FROM BEING REQUIRED FOR EACH DEPLOYER TO EITHER BEING IN A REGIONALLY PROXIMAL SERVICE CONTROLLED CONTINGENCY STOCK PROGRAM OR INTO A "BE PREPARED TO ACQUIRE" STATUS. THIS IS MEANT TO

UNCLASSIFIED

**UNCLASSIFIED**

BALANCE RESOURCING WITH CURRENT RISK BASED ON EXISTING LIMITATIONS OF ACQUISITION SUPPLY CHAINS FOR SELECT MCDM AND CHANGING THREAT DRIVERS FOR MCDM WITHIN THE USCENTCOM AOR.

**3.B.** (U) TERMS OF REFERENCE.

**3.B.1.** (U) MCDM. MCDM ARE CLASS VIII MEDICAL SUPPLY ITEMS THAT SERVE AS COUNTER-MEASURES FOR SPECIFIC CBRN AGENTS AND THREATS.

**3.B.2.** (U) INDIVIDUAL PROTECTIVE EQUIPMENT (IPE). ANNEXES C, W, AND U OF REF A DESCRIBES THE SPECIFIC IPE REQUIRED, THEIR AMOUNT, AND THEIR AVAILABILITY REQUIREMENTS IN THE USCENTCOM AOR.

**3.B.3.** (U) CONTINGENCY STOCK ITEM (CSI).

**3.B.3.A.** (U) CSI ARE CONTROLLED AND MAINTAINED IAW SERVICE SPECIFIC REQUIREMENTS BY USCENTCOM SERVICE COMPONENTS, AND RELEASED WHEN REQUIRED FOR USE AS IPE. CONSISTENT WITH AUTHORITIES IN REF D, USCENTCOM REQUIRES CBRN CSI (ITEMS 4.B. AND 4.C. OF THIS MESSAGE) BE MANAGED ACCORDINGLY:

**3.B.3.A.1.** (U) ENROLLED AND MAINTAINED IN THE SHELF-LIFE EXTENSION PROGRAM PER GUIDANCE IN REF C.

**3.B.3.A.2.** (U) CSI WILL BE STORED IN A REGIONALLY PROXIMAL LOCATION IN ORDER TO ALLOW TRANSFER TO THE CONTROL OF THE SUPPORTED COMMANDER FOR FURTHER DISPOSITION WITHIN 72 HOURS OF RELEASE.

**3.B.3.B.** (U) SERVICE COMPONENTS WILL ENSURE SERVICE PERSONNEL CONTINUE TO DEPLOY WITH ITEMS THAT ARE LISTED AS CSI IF THERE ARE INSUFFICIENT STOCKS TO MEET THE PROXIMITY/AVAILABILITY REQUIREMENTS OF PARAGRAPH 3.B.3.A.2.

**3.B.4.** (U) BE PREPARED TO ACQUIRE (BPT-A). THESE ARE ITEMS THAT SERVICE COMPONENTS WILL BE PREPARED TO PURCHASE OR PROCURE THROUGH SERVICE PROGRAMS AND / OR THE DOD SUPPLY CHAIN IN ORDER TO DISTRIBUTE IN A MANNER DICTATED UPON IDENTIFICATION OF CREDIBLE THREAT INDICATIONS AND WARNINGS.//

**4.** (U) THEATER MCDM REQUIREMENTS. THE FOLLOWING MCDM ITEM ALLOCATIONS AND AVAILIBILITIES CONSTITUTE THE MINIMUM REQUIREMENT FOR THE USCENTCOM THEATER IAW APPLICABILITY REQUIREMENTS OUTLINED IN PARA 2.

**4.A.** (U) M291A SKIN DECONTAMINATION KIT OR REACTIVE SKIN DECONTAMINATION LOTION (RSDL).

**4.A.1.** (U) ALLOCATION: ONE M291AKIT OR ONE POUCH CONTAINING 3 PACKETS OF RSDL PER AFFECTED INDIVIDUAL.

**4.B.** (U) LEVEL OF AVAILABILITY: REQUIRED AS IPE FOR ALL FORCES.

**4.C.** (U) ANTIDOTE TREATMENT NERVE AGENT AUTOINJECTOR (ATNAA) (6505-01- 362-7427).

**4.D.** (U) ALLOCATION: THREE EACH PER INDIVIDUAL.

**4.D.1.** (U) LEVEL OF AVAILABILITY: MAINTAINED AS CSI.

**4.E.** (U) DIAZEPAM INJECTION (CANA) (6505-01-274- 0951).

**4.E.1.** (U) ALLOCATION: ONE EACH PER INDIVIDUAL.

**4.E.2.** (U) LEVEL OF AVAILABILITY: MAINTAINED AS CSI.

**4.F.** (U) CIPROFLOXACIN 500MG TABS OR DOXYCYCLINE 100MG TABS.

**UNCLASSIFIED**

UNCLASSIFIED

**4.F.1.** (U) ALLOCATION: SIX TABS (BLISTER PACKS PREFERABLE) PER AFFECTED INDIVIDUAL OF EITHER MEDICATION TO COVER INITIAL DOSAGE AND SUPPORT PROPHYLAXIS AND/OR TREATMENT FOR THREE DAYS PER INDIVIDUAL.

AVAILABILITY OF COMPLETE 30-DAY COURSE OF MEDICATION (60 TABLETS) SHOULD BE CONSIDERED GIVEN MISSION REQUIREMENTS. INDIVIDUALS USING DOXYCYCLINE FOR MALARIA PROPHYLAXIS MAY BE CONSIDERED TO BE COVERED FOR THESE REMAINING DOSES.

**4.F.2.** (U) LEVEL OF AVAILABILITY: BPT-A.

**4.G.** (U) PYRIDOSTIGMINE BROMIDE (PB) 30MG TABS (SOMAN NERVE AGENT PRETREATMENT PYRIDOSTIGMINE - SNAPP).

**4.G.1.** (U) ALLOCATION: 42 TABLETS PER INDIVIDUAL.

**4.G.2.** (U) LEVEL OF AVAILABILITY: BPT-A.

**4.H.** (U) POTASSIUM IODIDE (KI) TABLETS (FOR BETA/GAMMA RADIATION EXPOSURE).

**4.H.1.** (U) ALLOCATION: 14 TABS PER AFFECTED INDIVIDUAL.

**4.H.2.** (U) LEVEL OF AVAILABILITY: BPT-A.//

**5.** (U) COORDINATING INSTRUCTIONS.

**5.A.** (U//FOUO) CSI STOCKS MUST BE MAINTAINED IN SUFFICIENT QUANTITY TO SUPPORT APPLICABLE CURRENT THEATER POPULATION.

**5.B.** (U) USCENTCOM COMPONENTS RETAIN THE AUTHORITY TO DIRECT THE ISSUE ITEMS LISTED AS EITHER CSI OR BPT-A BASED UPON MISSION REQUIREMENTS AND SERVICE REQUIREMENTS.

**6.** (U) POINTS OF CONTACT FOR THIS MESSAGE ARE: MR JAMES K. SJOVALL, CCSG-PLANS, 813-529-0345, [JAMES.K.SJOVALL.CIV@MAIL.MIL](mailto:JAMES.K.SJOVALL.CIV@MAIL.MIL) / @MAIL.SMIL.MIL; MAJ GARRION JACKSON, CCSG-MEDLOG, 813-529-0345, [GARRION.L.JACKSON2.MIL@MAIL.MIL](mailto:GARRION.L.JACKSON2.MIL@MAIL.MIL) / @MAIL.SMIL.MIL.//

UNCLASSIFIED